Neuphoria Therapeutics (NEUP) Tax Provisions (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Tax Provisions of -$34793.0 for Q1 2026, up 57.14% year-over-year from -$22140.8 in Q1 2025, and little changed on a QoQ basis from -$34794.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Tax Provisions data on file, last reported at -$34793.0 in Q1 2026.
- Quarterly Tax Provisions rose 57.14% year-over-year to -$34793.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$370982.0 (down 283.61% YoY) and the FY2025 annual result came in at -$468366.0, down 1003.26% from the prior year.
- Tax Provisions was little changed at -$34793.0 in Q1 2026 per NEUP's latest filing, from -$34794.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $105057.0 in Q2 2024 and bottomed at -$266602.0 in Q2 2025.
- The 4-year median for Tax Provisions is -$34793.0 (2023), against an average of -$47353.9.
- The widest annual swing landed in 2024, when Tax Provisions soared 133.36%; it then sank 595.55% in 2025.
- Tracing NEUP's Tax Provisions over 4 years: stood at -$34794.0 in 2023, then soared by 133.36% to $11609.0 in 2024, then plunged by 399.72% to -$34794.0 in 2025, then grew by 0.0% to -$34793.0 in 2026.
- Per Business Quant, the three latest NEUP Tax Provisions figures stand at -$34793.0 (Q1 2026), -$34794.0 (Q4 2025), and -$34793.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -34,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,793.00 |
| Dec 31, 2025 | -34,794.00 |
| Sep 30, 2025 | -34,793.00 |
| Jun 30, 2025 | 201,825.00 |
| Mar 31, 2025 | -81,186.00 |
| Dec 31, 2024 | 11,609.00 |
| Sep 30, 2024 | -132,187.00 |
| Jun 30, 2024 | -34,116.00 |
| Mar 31, 2024 | 16,383.00 |
| Dec 31, 2023 | -34,794.00 |
| Sep 30, 2023 | -34,793.00 |